Opportunities & Challenges toward the Clinical Application of ctDNA MRD Testing in Solid Cancers
This webinar is a recorded presentation of a live broadcast and includes a pre-test, the presentation, handout, and a post-test.
CME and CMLE credits are not available for this webinar.
This presentation will cover the evidence that circulating tumor DNA (ctDNA) minimal residual disease (MRD) can predict the development of cancer relapse in solid tumors and guide treatment personalization. In addition, we will discuss key issues for clinical implementation of ctDNA MRD testing, including the biology of ctDNA release, accounting for technical and biological background, determining the ideal timing of blood draws, and choosing a clinical assay.
1. Identify challenges, and list possible solutions, unique to cfDNA assay validation.
2. Discuss opportunities for circulating tumor DNA assessment in oncology practices.
3. Discuss limitations of ctDNA assessment in oncology practices.
 |
 |
|---|---|
| Speaker: Everett Moding, MD, PhD |
Moderator: Lynette M. Sholl, MD |
Recording Date: September 28, 2021
Duration: 1 hr
Level of Instruction: Basic
Continuing Education Credit Information
CME and CMLE credits are not available for this webinar.
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation